Literature DB >> 24518393

Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent.

Peter Kar Han Lau1, Gabriel Lee, Michael Bynevelt, Anna K Nowak.   

Abstract

Primary spinal glioblastoma (GBM) is a rare spinal tumour and is considered to have poor prognosis. We describe a case of a 17-year-old adolescent boy with a cervical spine GBM presenting with neck pain and right upper limb weakness. Initial spinal MRI demonstrated a 4.5 cm lesion extending from C2 to C5 suspicious for demyelination. Despite high-dose corticosteroids, his weakness progressed resulting in quadriparesis. Subsequent laminectomy and biopsy confirmed spinal GBM. Shortly after surgery the patient continued to deteriorate and was essentially bedbound. Standard chemoradiotherapy as per the Stupp protocol, together with multimodal rehabilitation, resulted in substantial functional improvement within 6 weeks of initiation. Continued functional improvement was observed for a period of 11 months. Although an Eastern Cooperative Oncology Group (ECOG) performance score of 4 would normally preclude chemoradiotherapy, a prolonged response to treatment and return to independent function were observed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518393      PMCID: PMC3926379          DOI: 10.1136/bcr-2013-202791

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

1.  Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2010-08-01       Impact factor: 4.130

2.  Intracranial metastases from malignant spinal-cord astrocytoma. Case report.

Authors:  D L Johnson; S Schwarz
Journal:  J Neurosurg       Date:  1987-04       Impact factor: 5.115

3.  Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.

Authors:  Han-Min Tseng; Lu-Ting Kuo; Huang-Chun Lien; Kao-Lang Liu; Mu-Tai Liu; Chao-Yuan Huang
Journal:  Anticancer Drugs       Date:  2010-11       Impact factor: 2.248

4.  The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.

Authors:  David E Gerber; Stuart A Grossman; Michel Zeltzman; Michele A Parisi; Lawrence Kleinberg
Journal:  Neuro Oncol       Date:  2006-11-15       Impact factor: 12.300

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases.

Authors:  Mariarita Santi; Hernando Mena; Kondi Wong; Kelly Koeller; Cara Olsen; Elisabeth J Rushing
Journal:  Cancer       Date:  2003-08-01       Impact factor: 6.860

7.  Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients.

Authors:  Matthew J McGirt; Ira M Goldstein; Kaisorn L Chaichana; Michael E Tobias; Karl F Kothbauer; George I Jallo
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

Review 8.  Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review.

Authors:  Wook Ha Kim; Wook-Ha Kim; Sang Hoon Yoon; Chae-Yong Kim; Ki-jeong Kim; Min Mi Lee; Gheeyoung Choe; In-Ah Kim; Jee Hyun Kim; Yu Jung Kim; Hyun-Jib Kim
Journal:  J Neurooncol       Date:  2010-06-05       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.